Solid Lipid Nanoparticles for Poorly Soluble Bioactive Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bioactive compounds face challenges such as poor solubility, enzymatic degradation, instability due to environmental factors, and limited bioavailability, which hinder their efficacy in conventional formulations, particularly in pharmaceutical, nutraceutical, and cosmetic applications.
Innovation Solution
Solid lipid nanoparticles (SLNs) are developed to encapsulate bioactive compounds, providing a biocompatible lipid matrix with a surfactant coating, ensuring a diameter of 10 nm to 1000 nm, a polydispersity index of less than 0.30, and a zeta potential of at least 25 mV, enhancing stability and bioavailability through controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bioactive compounds are used in conventional formulations, then therapeutic effects can be achieved, but poor solubility and low bioavailability limit their effectiveness
Solution Approach 1:
The patent uses solid lipid nanoparticles as an intermediary carrier system to deliver hydrophobic bioactive compounds. The lipid matrix acts as a mediator that solubilizes poorly water-soluble compounds, enabling their delivery in aqueous environments while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent transforms the physical state and delivery parameters of bioactive compounds by encapsulating them in nanoparticle form. This changes the compounds from poorly soluble molecular forms to dispersed nanoparticle systems with enhanced solubility, stability, and bioavailability.
2Reliability
If bioactive compounds are administered in high doses to overcome poor absorption, then therapeutic effects may be achieved, but the need for higher or more frequent dosing increases complexity and reduces ease of use
Solution Approach 1:
The solid lipid nanoparticle system provides sustained and controlled release of bioactive compounds, maintaining continuous therapeutic action. This eliminates the need for frequent dosing while ensuring consistent therapeutic effects, thereby improving ease of operation.
3Productivity
If bioactive compounds are exposed to environmental factors, then they can be delivered to the target site, but instability due to heat, light, and oxidation reduces their efficacy
Solution Approach 1:
The patent applies preliminary protective action by encapsulating bioactive compounds in solid lipid nanoparticles before exposure to environmental factors. The lipid matrix and surfactant coating provide pre-established protection against heat, light, and oxidation, preventing degradation before it occurs.
Solution Approach 2:
The patent uses a surfactant coating to form a flexible protective shell around the lipid nanoparticle core. This thin film barrier protects the encapsulated bioactive compounds from environmental degradation while allowing the particles to maintain their delivery function.
4Reliability
If highly pigmented bioactives like phycocyanin are used, then nutritional and therapeutic benefits are achieved, but intense green pigmentation and odor present aesthetic and formulation challenges
Solution Approach 1:
The patent extracts or masks the unwanted sensory properties (intense color and odor) of highly pigmented bioactives by encapsulating them in solid lipid nanoparticles. The lipid matrix and surfactant coating shield the pigmented compounds, eliminating aesthetic challenges while preserving therapeutic benefits.
5Reliability
If large-molecule proteins are delivered orally or transdermally, then therapeutic potential is achieved, but molecular size and instability limit permeability through biological membranes
Solution Approach 1:
The patent segments large-molecule proteins into nanoparticle-sized units (10-1000 nm). This size reduction through nanoparticulation enables the proteins to permeate biological membranes via oral or transdermal routes while maintaining their therapeutic integrity and potential.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SLNs protect bioactives from degradation, improve solubility and absorption, and enable sustained release, addressing sensory challenges and providing flexible administration routes, thereby improving therapeutic and cosmetic applications.
Implementation Method 1
a biocompatible lipid matrix that enhances stability, bioavailability, and controlled release
Implementation Method 2
stabilized by surfactants
Data Source
AI summary
Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.